Chemistry: natural resins or derivatives; peptides or proteins; – Proteins from micro-organisms – Bacteria
Reexamination Certificate
2008-03-04
2008-03-04
Campell, Bruce (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins from micro-organisms
Bacteria
C530S350000, C435S071100, C424S176100, C424S206100, C424S209100
Reexamination Certificate
active
07339037
ABSTRACT:
The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an antiviral protein, antiviral peptide, or antiviral conjugate comprising at least nine contiguous amino acids of SEQ ID NO: 2, wherein the at least nine contiguous amino acids are nonglycosylated and have antiviral activity, whereupon the influenza viral infection is inhibited.
REFERENCES:
patent: 3470067 (1969-09-01), Warren et al.
patent: 4795740 (1989-01-01), Cohen et al.
patent: 5104854 (1992-04-01), Schlesinger et al.
patent: 5266478 (1993-11-01), Chang et al.
patent: 5445960 (1995-08-01), Masuho et al.
patent: 5558865 (1996-09-01), Ohno
patent: 5618922 (1997-04-01), Ohno et al.
patent: 5821081 (1998-10-01), Boyd et al.
patent: 6015876 (2000-01-01), Boyd
patent: 6420336 (2002-07-01), Boyd
patent: 6780847 (2004-08-01), Boyd
patent: 6987096 (2006-01-01), Boyd et al.
patent: 2124545 (1995-11-01), None
patent: 3828842 (1989-10-01), None
patent: 459779 (1991-12-01), None
patent: 465979 (1992-01-01), None
patent: 503916 (1992-09-01), None
patent: 516135 (1992-12-01), None
patent: 581353 (1994-02-01), None
patent: 6141885 (1994-05-01), None
patent: 95939 (1991-09-01), None
patent: WO 90/12868 (1990-11-01), None
patent: WO 91/09625 (1991-07-01), None
patent: WO 91/11198 (1991-08-01), None
patent: WO 91/17764 (1991-11-01), None
patent: WO 92/07878 (1992-05-01), None
patent: WO 92/08491 (1992-05-01), None
patent: WO 92/08983 (1992-05-01), None
patent: WO 92/15885 (1992-09-01), None
patent: WO 93/04090 (1993-03-01), None
patent: WO 93/06216 (1993-04-01), None
patent: WO 93/12232 (1993-06-01), None
patent: WO 94/04574 (1994-03-01), None
patent: WO 94/07922 (1994-04-01), None
patent: WO 94/19017 (1994-09-01), None
patent: WO 94/28933 (1994-12-01), None
patent: WO 95/06119 (1995-03-01), None
patent: WO 95/24215 (1995-09-01), None
patent: WO 96/02273 (1996-02-01), None
patent: WO 96/34107 (1996-10-01), None
patent: WO 96/40294 (1996-12-01), None
patent: WO 99/19500 (1999-04-01), None
Bosse et al., Protective Local and Systemic Antibody Responses of Swine Exposed to an Aerosol ofActinobacillus pleuropneumoniaeSerotype 1, 1992, Infection and Immunity, vol. 60, No. 2, pp. 479-484.
Pouwels et al., The potential ofLactobacillusas a carrier for oral immunization: Development and preliminary characterization of vector systems for targeted delivery of antigens, 1996, Journal of Biotechnology, 1996, vol. 44, pp. 183-192.
Rubenstein et al., Increase of the Intestinal Absorption of Gentamincin and Amikacin by a Nonionic Surfactant, 1981, Antimicrobial Agents and Chemotherapy, vol. 19, No. 5, pp. 696-699.
Abuchowski et al.,Journal of Biological Chemistry, 252(11), 3578-3581 (1997).
Abuchowski et al., “Soluble Polymer-Enzyme Adducts,”in Enzymes as Drugs, Holcenberg et al., eds., John Wiley: New York, 1981, pp. 367-383.
Agnew et al.,Sexually Transmitted Diseases, 22 (5), 269-273 (1995).
Andreu et al.,J. Infect. Diseases, 171, 1237-1243 (1995).
Arthos et al.,J. Biological Chem., 277(13), 11456-11464 (2002).
Aullo et al.,EMBO Journal, 11(2), 575-583 (1992).
Balter,Science, 266, 1312-1313 (1994).
Banga et al.,International Journal of Pharmaceutics, 48, 15-50 (1988).
Barry, “The Transdermal Route for the Delivery of Peptides and Proteins,”in Delivery Systems for Peptide Drugs, Davis et al., eds., Plenum Press: New York, 1986, pp. 265-275.
Berzofsky,Journal of Acquired Immune Deficiency Syndromes, 4, 451-459 (1991).
Bird,AIDS, 5(7), 791-796 (1991).
Bourinbaiar et al.,Life Science, 54(1), 5-9 (1994).
Bourinbaiar et al.,Contraception, 49, 131-137 (1994).
Bowie et al.,Science, 247, 1306-1310 (1990).
Boyd et al.,Journal of Medicinal Chemistry, 37(12), 1740-1745 (1994).
Boyd et al.,Antimicrobial Agents and Chemotherapy, 41(7), 1521-1530 (1997).
Boyd, “Strategies for the Identification of New Agents for the Treatment of AIDS: A National Program to Facilitate the Discovery and Preclinical Development of New Drug Candidates for Clinical Evaluation,”AIDS Etiology, Diagnosis, Treatment, and Prevention, Second Edition, DeVita et al., eds., J.B. Lippincott Company, 1988, pp. 305-317.
Bray et al.,J. of Infectious Diseases, 178, 651-661 (1998).
Bruce et al.,Can. J. Microbiol., 34, 339-343 (1988).
Buckheit et al.,Antiviral Research, 25, 43-56 (1994).
Buckheit et al.,Aids Research and Human Retroviruses, 10(11), 1497-1506 (1994).
Capon et al.,Nature, 337, 525-531 (1989).
Capon et al.,Annu. Rev. Immunol., 9, 649-678 (1991).
Carone et al.,The Journal of Laboratory and Clinical Medicine, 100(1), 1-14 (1982).
Carpenter et al.,JAMA, 280(1), 78-86 (1998).
Carter et al.,J. Org. Chem., 49, 236-241 (1984).
Chan et al.,Cell, 93, 681-684 (1998).
Chaudhary et al., “CD4-PE4O—A Chimeric Toxin Active Against Human Immunodeficiency Virus (HIV)-Infected Cells,”The Human Retroviruses, pp. 379-387 (1991).
Chaudhary et al.,Nature, 335, 369-372 (1988).
Coffin, John M.,Science, 267, 483-489 (1995).
Cohen et al.,JAMA 280(1), 87-88 (1998).
Cohen,Science, 267, 179 (1995).
Coll et al.,Journal of Natural Products, 49(5), 934-936 (1986).
Davey et al.,Journal of Infectious Diseases, 170, 1180-1188 (1994).
Davis,J. Pharm. Pharmacol., 44(Suppl. 1), 186-190 (1992).
Davis, et al.,Peptide and Protein and Drug Delivery, Marcel Dekker, Inc., New York: 1991 (831-864).
De Clercq,Advances In Virus Research, 42, 1-55 (1993).
De Clercq,Journal of Acquired Immune Deficiency Syndromes, 4(3), 207-218 (1991).
Deasy et al.,in Microencapsulation and Related Processes, Swarbrick J., ed., Marcel Dekker, Inc.: New York, 1984, pp. 1-60.
DeNoon, “AIDS Therapies (Monoclonal Antibodies): Anti-HIV Immunoglobulin Recombinants Shine in Ex Vivo Studies,”AIDSWeekly Plus(May 13, 1996).
Denton et al.,Int. J. Cancer, 57, 10-14 (1994).
Dey et al.,J. Virol., 74 (10), 4562-4569 (May 2000).
Dropulic et al.,Human Gene Therapy, 5, 927-939 (1994).
Eck et al.,The Pharmacological Basis of Therapeutics, McGraw Hill, New York, Chapter 5, 77-101 (1995).
Elmer et al.,JAMA, 275(11), 870-876 (1996).
Emtage, “Biotechnology and Protein Production,”in Delivery Systems for Peptide Drugs, Davis et al., eds., Plenum Press: New York, 1986, pp. 23-33.
Eppstein et al.,CRC Critical Reviews in Therapeutic Drug Carrier Systems, 5(2), 99-139 (1988).
Essex et al.,Leukemia, 9, (Supp 1) S71-S74 (1995).
Faulkner,Natural Product Reports, pp. 355-394 (1994).
Frankmölle et al.,The Journal of Antibiotics, 45(9), 1451-1457 (1992).
Freed et al.,Bull. Inst. Pasteur, 88, 73-110 (1990).
Fung et al.,J. Immunol., 145(7), 2199-2206 (1990).
Glombitza et al.,in Algal and Cyanobacterial Biotechnology, Cresswell, R.C., et al., eds., 1989, pp. 211-218.
Goudswaard et al.,Scand. J. Immunol., 8, 21-28 (1978).
Greenspan et al.,The FASEB Journal, 7, 437-444 (1993).
Grossman et al.,Nature Genetics, 6, 335-341 (1994).
Gulakowski et al.,Journal of Virological Methods, 33, 87-100 (1991).
Gustafson et al.,J. Med. Chem., 35, 1978-1986 (1992).
Guyden, “Techniques for Gene Cloning and Expression,”in Recombinant DNA Technology Concepts and Biomedical Applications, Steinberg et al., eds., Prentice Hall: Englewood Cliffs, NJ, 1993, pp. 81-124 and 150-162.
Harris, “Introduction to Biotechnical and Biomedical Applications of Poly(Ethylene Glycol)”,Poly(Ethylene Glycol)Chemistry: Biotechnical and Biomedical Applications, Plenum Press, New York: 1992 (1-14).
Harris et al.,J. Infectious Diseases, 176(5), 1388-1392 (1997).
Haynes,The Lancet, 348(9043), 1741 (1996) (abstract only).
Hillier et al.,Clinical Infectious Diseases, 16, S273-S281 (1993).
Hillier, “A Healthy Vaginal Ecosystem is Important for Prevention of HIV Transmission: Why and How?” presented atConference on Advances in AIDS Vaccine Development, Bethesda, Maryland (Feb. 11-15, 1996).
Holmberg et al., “Immobilization of Proteins via PEG Chains”,Poly(Ethylene Glycol)Chemistry: Biotechnical and Biomedical Applications, Plenum Press, New York: 1992, pp.
Boyd Michael R.
Gronenborn Angela M.
Mori Toshiyuki
O'Keefe Barry R.
Blumel Benjamin P.
Campell Bruce
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Glycosylation-resistant cyanovirins and related conjugates,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycosylation-resistant cyanovirins and related conjugates,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosylation-resistant cyanovirins and related conjugates,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2791673